Investorideas.com Newswire - Hydrogen and Fuel Cells: "An Industry on the Move" in the Clean Energy Game
Snapshot of Hydrogenics (TSX: HYG), Ballard (NASDAQ:BLDP)
New York, NY , Point Roberts WA– Tuesday July 9th, 2013 – (www.investorideas.com newswire,) Taylor Van Zant of Investorideas.com., an investor research portal specializing in sector research for independent investors, reports on the Hydrogen and Fuel Cell market and the recent Hydrogen + Fuel Cell C Conference (HFC 2013 ) (http://www.hfc2013.com/), held in Vancouver June 16th – 19th, 2013.
Clean, renewable energy continues to be a growing industry as more and more countries across the globe are forced, or choose, to implement more environmentally conscious energy plans. In this renewable energy emergence market Hydrogen and Fuel cell technology is fast becoming a rising star.
This year, the sixth Hydrogen + Fuel Cell Conference took place at the Vancouver Convention Center, hosting some of the leading developers and innovation in the Hydrogen and Fuel cell industry as well as some high profile public companies showcasing their latest developments.
The British Columbia Ministry of Tourism, Trade and Investment is promoting, and with good reason, the Province to investors as the home to the world’s third-largest clean technology cluster. Dozens of fuel cell companies and research organizations are located in B.C such as the National Research Council Institute for Fuel Cell Innovation (NRC-IFCI); the Canadian Hydrogen and Fuel Cell Association; the Automotive Fuel Cell Cooperation; UBC’s Clean Energy Research Centre; NuCellSys; Powertech Labs; and Westport Innovations.
With roughly 70 per cent of Canada’s fuel cell sector centered in or around Metro Vancouver, the city made a great stage for the HFC conference and researchers and industry leaders from around the world were happy to be a part of such a large scale promotion of this lesser known industry.
Fuel Cell technology implementation has faced the obstacles of the recession in the last few years and the obvious troubles related to cost efficiency, but the industry is now making a strong recovery and proving to be beneficial to other sectors of the green energy industry.
A little about Hydrogen and Fuel Cells:
There are a variety of benefits to using fuel cells, and especially Hydrogen based ones, as fuel cells have a higher efficiency than diesel or gas engines and most fuel cells operate silently, compared to internal combustion engines. This makes them ideal for use within buildings such as hospitals or on military compounds across the globe. Fuel cells can eliminate pollution caused by burning fossil fuels; for hydrogen fuelled fuel cells, the only by-product at point of use is water. If the hydrogen comes from the electrolysis of water driven by renewable energy, then using fuel cells eliminates greenhouse gases over the whole cycle. Fuel cells do not need conventional fuels such as oil or gas and can therefore reduce economic dependence on oil producing countries, creating greater energy security for the user nation. Since hydrogen can be produced anywhere where there is water and a source of power, generation of fuel can be distributed and does not have to be grid-dependent. The use of stationary fuel cells to generate power at the point of use allows for a decentralized power grid that is potentially more stable. Another military feature of some low temperature fuel cells (PEMFC, DMFC) is there low heat transmission which makes them ideal for covert military applications. Higher temperature fuel cells produce high-grade process heat along with electricity and are well suited to cogeneration applications (such as combined heat and power for residential use). Operating times are much longer than with batteries, since doubling the operating time needs only doubling the amount of fuel and not the doubling of the capacity of the unit itself. Unlike batteries, fuel cells have no "memory effect" when they are getting refueled. The maintenance of fuel cells full article: http://www.investorideas.com/news/2013/renewable-energy/07092.asp#
Tuesday, July 09, 2013
Investorideas.com - How to profit from the shale revolution in Latin America
Investorideas.com - How to profit from the shale revolution in Latin America
A small company with big potential in Colombia; (TSX:CNE), (bvc:CNEC)
By: James McKeigue, MoneyWeek
July 9, 2013 (Investorideas.com energy stocks newswire) What do the Russian government and Greenpeace have in common? They both fear the spread of America's shale gas revolution. The former worries that if shale takes off elsewhere it will weaken its position in the market, while the latter dreads the supposed environmental consequences of global shale production.
I'm sure you have all heard about shale gas by now, but just to recap, shale gas is natural gas trapped within shale rock formations. Over the past decade, new drilling methods and a process called hydraulic fracturing ('fracking'), which involves pumping a mix of pressurised water, sand and chemicals underground to crack underground rocks and free the gas. Producers now have access to gas that was once uneconomic to extract.
So far the 'shale revolution' has been largely confined to the US , where there is so much of the stuff, there has been a glut. This has helped to drive prices of natural gas to new lows in recent years.
But attempts to launch it elsewhere have failed. For example, after wasting millions of dollars drilling failed wells in Poland – supposedly Europe's best shale prospect – ExxonMobil pulled out of the country last year.
full article http://www.investorideas.com/news/2013/energy/07091.asp#
A small company with big potential in Colombia; (TSX:CNE), (bvc:CNEC)
By: James McKeigue, MoneyWeek
July 9, 2013 (Investorideas.com energy stocks newswire) What do the Russian government and Greenpeace have in common? They both fear the spread of America's shale gas revolution. The former worries that if shale takes off elsewhere it will weaken its position in the market, while the latter dreads the supposed environmental consequences of global shale production.
I'm sure you have all heard about shale gas by now, but just to recap, shale gas is natural gas trapped within shale rock formations. Over the past decade, new drilling methods and a process called hydraulic fracturing ('fracking'), which involves pumping a mix of pressurised water, sand and chemicals underground to crack underground rocks and free the gas. Producers now have access to gas that was once uneconomic to extract.
So far the 'shale revolution' has been largely confined to the US , where there is so much of the stuff, there has been a glut. This has helped to drive prices of natural gas to new lows in recent years.
But attempts to launch it elsewhere have failed. For example, after wasting millions of dollars drilling failed wells in Poland – supposedly Europe's best shale prospect – ExxonMobil pulled out of the country last year.
full article http://www.investorideas.com/news/2013/energy/07091.asp#
Q&A with Chairman & CEO of Aethlon Medical (OTCQB: AEMD) Discussing FDA approval of IDE to Treat Hepatitis C (HCV) Patients and What's Next for the Aethlon Hemopurifier®
Point Roberts, WA, New York, NY - July 9, 2013 (Investorideas.com
newswire) Investorideas.com, an investor research portal specializing in
investing ideas in leading sectors including biotech and medical
technology stocks, issues an exclusive Q&A with Aethlon Medical,
Inc. (OTCQB: AEMD),
following recent news that the United States FDA has approved an
Investigational Device Exemption (IDE) that allows the Company to
initiate human feasibility studies of the Aethlon Hemopurifier® in the
United States for the treatment of Hepatitis C virus (HCV).
Mr. James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
discusses the path to reach this milestone and what’s next for the
Aethlon Hemopurifier®.
Q: Investorideas.com
Jim can you tell us what the significance of the recent FDA approval is to Aethlon and a short synopsis of the road taken to get here?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
In regards to significance, our Hemopurifier® is the first medical device of its kind to be cleared by FDA for human studies in the United States. Based on previous treatment outcomes, our initial target is the elimination of circulating Hepatitis C virus. As we advance clinically, we plan to expand the indications for our Hemopurifier into other infectious disease and cancer targets. Regarding the road to get here? This all started out as a theoretical concept of a device that could selectively eliminate a broad-spectrum of disease targets from the entire circulatory system. With the approval from FDA to start U.S. studies, we are taking a major step toward turning our original vision into a reality.
Q: Investorideas.com
Can you explain the steps and timeline for the first feasibility study?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
We expect the study to kick-off toward year-end with completion expected toward the end of Q1 or early Q2 of 2014. We are now preparing for a manufacturing run to support our studies here in the U.S. as well as a compassionate-use program that has been established in India.
Q: Investorideas.com
Separate from Hepatitis C virus (HCV), what other diseases can be potentially be targeted?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Well, we conducted a successful proof of principal study in a HIV-AIDS patient and have also had leading government and non-government researchers conduct studies to validate the broad-spectrum capabilities of the Hemopurifier against numerous bioterror and pandemic threats. However, outside of HCV we are most excited about the discovery that the Hemopurifier® captures tumor-secreted exosomes underlying cancer. These particles contribute to establishing and spreading metastasis and they are extremely immunosuppressive. In fact, the quantity of exosomes in circulation is in direct correlation with stage of cancer. So, if you don’t have cancer, exosomes shouldn’t be present. However, if you have stage-four cancer, the quantity of circulating exosomes can be massive. We believe our Hemopurifier® is the first therapeutic candidate to address this vital target in cancer and because of our early work in the field, we already have a patent issued to protect our exosome related endeavors.
Q: Investorideas.com
Following completion of the feasibility study; what’s next?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
We would move quickly to collaborate with FDA to establish the treatment protocol for a pivotal study, which is required prior to commercial launch. Additionally, we would seek to leverage our feasibility data into other therapeutic targets.
Q: Investorideas.com
With current treatments available for Hepatitis C virus (HCV) patients; can you explain how the Hemopurifier® compliments drug regiments as well as addresses needs when resistance to drug regimens arises?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Whether the treatment strategy is current interferon-based standard of care or emerging all-antivirals, our objective is to combine our Hemopurifier with therapy to accelerate the rate at which a patient first achieves undetectable HCV in circulation. In HCV care, the quicker an individual achieves undetectable viral load the higher the cure rate. As an example, only 11% of patients who initiate interferon-based therapy will achieve undetectable viral load at day 30 which is also known as a rapid viral response or RVR. Based on large-scale studies, RVR achievement equates to 86% cure rates versus less than 40% for non-RVR patients. We have demonstrated that a just a three treatment Hemopurifier® therapy regimen when administered to hard-to-treat HCV genotype 1 patients in combination with interferon-based therapy can achieve undetectable HCV in as little as seven days. We also envision that Hemopurifier® therapy will offer a solution to viral rebound patients who initially achieve undetectable viral load but then have the presence of virus reestablishing as a result of emerging drug resistance. This represents another opportunity for us to enhance the outcome of either all-antiviral or interferon-based therapies.
Q: Investorideas.com
The FDA news was a major milestone for the company and the Hemopurifier® but there are also major developments underway with the technology with Defense Advanced Research Projects Agency (DARPA). For new investors can you give them a brief outline where this stands?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Sure, the technology platform underlying our Hemopurifier® is being utilized as the basis for a new device to treat sepsis, which is a leading cause of death in wounded warfighters and civilians in the ICU. In this regard, we were initially awarded a $6.8 million contract and then recently were part of a group that won a follow-on contract worth $22 million. We hope to be in a position to share some of our sepsis treatment advances in the near future.
Q: Investorideas.com
For a small medical technology company Aethlon Medical now has an impressive track record for its core technology. You have stayed the course over time, in spite of market conditions and having to fund the company in less than ideal times for small business. Can you tell us about the driving force behind that conviction?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Getting to this point was hard. Think of the challenge. We were attempting to create a therapeutic mechanism that never previously existed and we would likely need to survive a decade or more without generating revenues in an industry where most therapeutic candidates never make it into human studies. However, when reflecting back, I could have never imagined that we would have the breadth of therapeutic opportunities that we have today in cancer, infectious disease and other life-threatening conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source - www.Investorideas.com
Q: Investorideas.com
Jim can you tell us what the significance of the recent FDA approval is to Aethlon and a short synopsis of the road taken to get here?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
In regards to significance, our Hemopurifier® is the first medical device of its kind to be cleared by FDA for human studies in the United States. Based on previous treatment outcomes, our initial target is the elimination of circulating Hepatitis C virus. As we advance clinically, we plan to expand the indications for our Hemopurifier into other infectious disease and cancer targets. Regarding the road to get here? This all started out as a theoretical concept of a device that could selectively eliminate a broad-spectrum of disease targets from the entire circulatory system. With the approval from FDA to start U.S. studies, we are taking a major step toward turning our original vision into a reality.
Q: Investorideas.com
Can you explain the steps and timeline for the first feasibility study?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
We expect the study to kick-off toward year-end with completion expected toward the end of Q1 or early Q2 of 2014. We are now preparing for a manufacturing run to support our studies here in the U.S. as well as a compassionate-use program that has been established in India.
Q: Investorideas.com
Separate from Hepatitis C virus (HCV), what other diseases can be potentially be targeted?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Well, we conducted a successful proof of principal study in a HIV-AIDS patient and have also had leading government and non-government researchers conduct studies to validate the broad-spectrum capabilities of the Hemopurifier against numerous bioterror and pandemic threats. However, outside of HCV we are most excited about the discovery that the Hemopurifier® captures tumor-secreted exosomes underlying cancer. These particles contribute to establishing and spreading metastasis and they are extremely immunosuppressive. In fact, the quantity of exosomes in circulation is in direct correlation with stage of cancer. So, if you don’t have cancer, exosomes shouldn’t be present. However, if you have stage-four cancer, the quantity of circulating exosomes can be massive. We believe our Hemopurifier® is the first therapeutic candidate to address this vital target in cancer and because of our early work in the field, we already have a patent issued to protect our exosome related endeavors.
Q: Investorideas.com
Following completion of the feasibility study; what’s next?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
We would move quickly to collaborate with FDA to establish the treatment protocol for a pivotal study, which is required prior to commercial launch. Additionally, we would seek to leverage our feasibility data into other therapeutic targets.
Q: Investorideas.com
With current treatments available for Hepatitis C virus (HCV) patients; can you explain how the Hemopurifier® compliments drug regiments as well as addresses needs when resistance to drug regimens arises?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Whether the treatment strategy is current interferon-based standard of care or emerging all-antivirals, our objective is to combine our Hemopurifier with therapy to accelerate the rate at which a patient first achieves undetectable HCV in circulation. In HCV care, the quicker an individual achieves undetectable viral load the higher the cure rate. As an example, only 11% of patients who initiate interferon-based therapy will achieve undetectable viral load at day 30 which is also known as a rapid viral response or RVR. Based on large-scale studies, RVR achievement equates to 86% cure rates versus less than 40% for non-RVR patients. We have demonstrated that a just a three treatment Hemopurifier® therapy regimen when administered to hard-to-treat HCV genotype 1 patients in combination with interferon-based therapy can achieve undetectable HCV in as little as seven days. We also envision that Hemopurifier® therapy will offer a solution to viral rebound patients who initially achieve undetectable viral load but then have the presence of virus reestablishing as a result of emerging drug resistance. This represents another opportunity for us to enhance the outcome of either all-antiviral or interferon-based therapies.
Q: Investorideas.com
The FDA news was a major milestone for the company and the Hemopurifier® but there are also major developments underway with the technology with Defense Advanced Research Projects Agency (DARPA). For new investors can you give them a brief outline where this stands?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Sure, the technology platform underlying our Hemopurifier® is being utilized as the basis for a new device to treat sepsis, which is a leading cause of death in wounded warfighters and civilians in the ICU. In this regard, we were initially awarded a $6.8 million contract and then recently were part of a group that won a follow-on contract worth $22 million. We hope to be in a position to share some of our sepsis treatment advances in the near future.
Q: Investorideas.com
For a small medical technology company Aethlon Medical now has an impressive track record for its core technology. You have stayed the course over time, in spite of market conditions and having to fund the company in less than ideal times for small business. Can you tell us about the driving force behind that conviction?
A: James A. Joyce, Chairman, CEO of Aethlon Medical, Inc.
Getting to this point was hard. Think of the challenge. We were attempting to create a therapeutic mechanism that never previously existed and we would likely need to survive a decade or more without generating revenues in an industry where most therapeutic candidates never make it into human studies. However, when reflecting back, I could have never imagined that we would have the breadth of therapeutic opportunities that we have today in cancer, infectious disease and other life-threatening conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source - www.Investorideas.com
Monday, July 08, 2013
Mobile Commerce Stock Alert: SAMY Launching in the Middle East - GCC Region and Turkey
DUBAI AND SARASOTA, Fla. - July 8, 2013 (Investorideas.com newswire)
via PRWEB - Ignivia Technologies FZCO, a leading services provider, and
MobileBits Corp., (OTCBB: MBIT),
provider of the SAMYSMmobile marketing and engagement network, today
announced they have signed a multi-year, exclusive master agreement to
sell SAMY in Turkey and the Middle East's Gulf Cooperation Council
Region (GCC), which includes the United Arab Emirates (UAE), Kuwait,
Bahrain, Qatar, Oman, Saudi Arabia, Jordan and Lebanon.
SAMY is the award-winning, patent-pending direct mobile marketing and engagement network that enables merchants and shopping centers to extend their brand to popular smartphones and engage with new and existing customers. SAMY also provides merchants an easy way to quickly integrate all the important retail touch points including point of sale (POS), gift cards, mobile offers, loyalty systems and more into one single, synchronized mobile platform.
"MobileBits has been gaining significant inroads in the European and American markets; we are delighted with this partnership and look forward to contributing to its continued success by adding another success story in the Middle East. There is a particularly robust outlook for mobile marketing and engagement solutions and our role will be to bring the best benefits and experience to both retailers and end users," said Mr. Yousef Shreim, President, Igniva Technologies.
According to AT Kearney, four of the Gulf States are in the top 20 countries of the 2013 Global Retail Development index with the UAE ranked fifth (5th), Kuwait ninth (9th), Saudi Arabia sixteenth (16th) and Oman seventeenth (17th).
"The Middle East has emerged as a hotbed of technology initiatives given the aggressive modernization projects being undertaken across the region. We view this as a very important strategic move that will strengthen both MobileBits and Igniva Technologies' presence in the region," added Mr. Yousef Shreim.
"We welcome the teams in the GCC region and Turkey. We believe that our SAMY re-seller model is uniquely designed for partners who have the ability to operate and manage the SAMY program in their country of experience," said Walter Kostiuk, President & CEO of MobileBits. "Ignivia brings an important sales and support component which will enable them to deliver tremendous value to the region's merchants and brands."
The GCC is the third territory where MobileBits has signed agreements with a master reseller partner to distribute SAMY. Earlier, MobileBits signed master agreements with partners in Italy and Russia, who recently expanded their partnership to include Ukraine; bringing the new total number of countries to sixteen (16).
About MobileBits Corporation
MobileBits, provider of SAMY, the fast growing 'Mobile Mall' that provides any merchant, retailer or brand with an out-of-the box, ready to deploy, mobile commerce platform to connect with consumers in their local area and help increase sales in the physical store. The solution provides businesses a complete set of tools to connect with, create and manage mobile campaigns, deals, offers, commerce, loyalty and rewards to a subscribed mobile consumer. For more information, visit http://www.mobilebits.com or http://www.samy.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially from forecasted results. These risks and uncertainties include our ability to: attract end users; attract advertisers; our ability to successfully implement our current long-term growth strategy; as well as product demand, market competition, fluctuations in advertising payouts, delays in website & application development, technical issues beyond our control, reliance on the various platforms that we build applications on, and risks inherent in our operations. For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.
For more information contact:
JoLynn Blatz
MobileBits Corp.
T: 941.225.6103
jolynn.blatz@mobilebits.com
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2013/7/prweb10898187.htm
Published at Investorideas.com newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products Or securities. Investorideas.com was compensated one hundred fifty dollars for this single news release.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
SAMY is the award-winning, patent-pending direct mobile marketing and engagement network that enables merchants and shopping centers to extend their brand to popular smartphones and engage with new and existing customers. SAMY also provides merchants an easy way to quickly integrate all the important retail touch points including point of sale (POS), gift cards, mobile offers, loyalty systems and more into one single, synchronized mobile platform.
"MobileBits has been gaining significant inroads in the European and American markets; we are delighted with this partnership and look forward to contributing to its continued success by adding another success story in the Middle East. There is a particularly robust outlook for mobile marketing and engagement solutions and our role will be to bring the best benefits and experience to both retailers and end users," said Mr. Yousef Shreim, President, Igniva Technologies.
According to AT Kearney, four of the Gulf States are in the top 20 countries of the 2013 Global Retail Development index with the UAE ranked fifth (5th), Kuwait ninth (9th), Saudi Arabia sixteenth (16th) and Oman seventeenth (17th).
"The Middle East has emerged as a hotbed of technology initiatives given the aggressive modernization projects being undertaken across the region. We view this as a very important strategic move that will strengthen both MobileBits and Igniva Technologies' presence in the region," added Mr. Yousef Shreim.
"We welcome the teams in the GCC region and Turkey. We believe that our SAMY re-seller model is uniquely designed for partners who have the ability to operate and manage the SAMY program in their country of experience," said Walter Kostiuk, President & CEO of MobileBits. "Ignivia brings an important sales and support component which will enable them to deliver tremendous value to the region's merchants and brands."
The GCC is the third territory where MobileBits has signed agreements with a master reseller partner to distribute SAMY. Earlier, MobileBits signed master agreements with partners in Italy and Russia, who recently expanded their partnership to include Ukraine; bringing the new total number of countries to sixteen (16).
About MobileBits Corporation
MobileBits, provider of SAMY, the fast growing 'Mobile Mall' that provides any merchant, retailer or brand with an out-of-the box, ready to deploy, mobile commerce platform to connect with consumers in their local area and help increase sales in the physical store. The solution provides businesses a complete set of tools to connect with, create and manage mobile campaigns, deals, offers, commerce, loyalty and rewards to a subscribed mobile consumer. For more information, visit http://www.mobilebits.com or http://www.samy.com.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the near future. There are a number of factors that could cause actual results and developments to differ materially from forecasted results. These risks and uncertainties include our ability to: attract end users; attract advertisers; our ability to successfully implement our current long-term growth strategy; as well as product demand, market competition, fluctuations in advertising payouts, delays in website & application development, technical issues beyond our control, reliance on the various platforms that we build applications on, and risks inherent in our operations. For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.
For more information contact:
JoLynn Blatz
MobileBits Corp.
T: 941.225.6103
jolynn.blatz@mobilebits.com
This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2013/7/prweb10898187.htm
Published at Investorideas.com newswire
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products Or securities. Investorideas.com was compensated one hundred fifty dollars for this single news release.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Friday, July 05, 2013
Solar Stocks Bounce: LDK, TSL, YGE, XSNX
New York, NY - July 5, 2013 (Investorideas.com renewable energy
stocks newswire) Investorideas.com, an investor research portal
specializing in sector research for independent investors, including
biotech and renewable energy stocks issues a trading alert for solar
stocks following the July 4th holiday . Friday’s session is seeing a
bounce in solar stocks, with some trading up over 7%.
Chinese solar stocks gained following a report from Shanghai
Securities News that China is planning to limit exports of solar panels
to the European Union to 10 gigawatts a year.
LDK Solar Co., Ltd. (NYSE LDK) is trading at $1.36, up 0.06 or 4.96% at 10:44AM EDT.
Trina Solar Limited (NYSE: TSL) is trading at $6.49, gaining 0.32 or 5.19% at 10:46AM EDT
Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) is trading at $3.58, gaining 0.26 or 7.83% at 10:41AM EDT on over 2 Million shares.
XSUNX Inc. (OTCBB: XSNX)
is trading at $0.0117, up 0.0007 or 6.36% as of 10:13AM EDT. The
Company is a developer of CIGSolar®, a patent-pending technology for the
mass production of CIGS solar cells that offers a capital-efficient,
low-cost alternative to the use of silicon solar cells.
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - tech, social media stocks, biotech stocks, water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: XSNX compensates Investorideas.com for news and content publishing and distribution averaging one thousand five hundred per month
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
LDK Solar Co., Ltd. (NYSE LDK) is trading at $1.36, up 0.06 or 4.96% at 10:44AM EDT.
Trina Solar Limited (NYSE: TSL) is trading at $6.49, gaining 0.32 or 5.19% at 10:46AM EDT Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) is trading at $3.58, gaining 0.26 or 7.83% at 10:41AM EDT on over 2 Million shares.
XSUNX Inc. (OTCBB: XSNX)
is trading at $0.0117, up 0.0007 or 6.36% as of 10:13AM EDT. The
Company is a developer of CIGSolar®, a patent-pending technology for the
mass production of CIGS solar cells that offers a capital-efficient,
low-cost alternative to the use of silicon solar cells.
About InvestorIdeas.com:InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more .
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for the free investor stock alerts http://www.investorideas.com/Resources/Newsletter.asp
Become an Investorideas.com Member and access our 14 online stock directories 24/7 - tech, social media stocks, biotech stocks, water, renewable energy, mining stocks and more…
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: XSNX compensates Investorideas.com for news and content publishing and distribution averaging one thousand five hundred per month
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source - www.Investorideas.com
Monday, July 01, 2013
Investorideas.com Newswire - Electric Car Stock Investor Alert; Tesla (TSLA) Gains on Analyst Upgrade
Investorideas.com Newswire - Electric Car Stock Investor Alert; Tesla (TSLA) Gains on Analyst Upgrade
Electric Car Stock Investor Alert; Tesla (TSLA) Gains on Analyst Upgrade
Point Roberts WA , New York, NY– July 1 , 2013 – (www.investorideas.com newswire) , Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including renewable energy stocks issues a trading alert for electric car stock Tesla Motors, Inc. (NasdaqGS :TSLA). Tesla is trading at
$114.53, gaining $7.17 or 6.68% at 12:24PM EDT on over 6.5 Million shares. The stock had a morning high of $116.20.
The stock moved following an analyst upgrade from Elaine Kwei at Jefferies, raising the price target to $130 from $70.
Full article
http://www.investorideas.com/news/2013/renewable-energy/07013.asp
Electric Car Stock Investor Alert; Tesla (TSLA) Gains on Analyst Upgrade
Point Roberts WA , New York, NY– July 1 , 2013 – (www.investorideas.com newswire) , Investorideas.com staff: Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including renewable energy stocks issues a trading alert for electric car stock Tesla Motors, Inc. (NasdaqGS :TSLA). Tesla is trading at
$114.53, gaining $7.17 or 6.68% at 12:24PM EDT on over 6.5 Million shares. The stock had a morning high of $116.20.
The stock moved following an analyst upgrade from Elaine Kwei at Jefferies, raising the price target to $130 from $70.
Full article
http://www.investorideas.com/news/2013/renewable-energy/07013.asp
Thursday, June 27, 2013
Investorideas.com - Viscount Systems (VSYS) - Emerging as the "Intel Inside" of Cloud Secure Access
Investorideas.com - Viscount Systems (VSYS) - Emerging as the "Intel Inside" of Cloud Secure Access
June 27, 2013 (Investorideas.com Newswire) SoundView Technology Group: Since initially covering the arrival of cloud-based technology for physical security back in October of 2012 the market in general and Viscount Systems (VSYS) in particular have been developing faster than expected.
Physical security and access control one of the last non-digital, proprietary and very large markets that is now shifting over to software and internet based solutions that leverage smartphones and IP networks. Viscount is the only company that has developed a pure software/internet solution.
Recently they have announced a partnership with Microsoft to be a key component of their Global Security Operations Center . We expect this agreement to be a building block to additional agreements with Microsoft (who with Active Directory already holds the keys to the digital security kingdom.) Viscount is also developing relationships with all the existing large players who are likely to use the Viscount solution for access control as part of their overall proposals.
Near-term business trends have been very positive with a reported pipeline of over $12M (versus their current revenue run rate of $4M/year). The next few quarters will be an important test for the expanded and experienced management team but the momentum and market is clearly on their side.
Viscount also has extensive patent protection (60 filed claims) that will help protect them and make them a more attractive partner to the massive firms serving the industry with old technology (Honeywell, Johnson Controls, ASSA ABLOY) and IT firms like Cisco that have tried to approach the market but whose solutions have been wanting.
Viscount stock has moved up nicely since our initial coverage report but remains well below our near-term expectation of $0.26 and our intrinsic value (IV) estimate of $0.82 for 2014.
Our brief update on current trends is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_June_2013.pdf
The original 20-page overview report is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_Oct_11_2012.pdf
Any questions please contact:
Kris Tuttle
Director of Research
SoundView Technology Group
kris@soundview.co
617-828-6462
More Info:
This news is published on the Investorideas.com Newswire and its syndicated partner network
News now!
Get Free investor news and stock alerts: Sign up here
Disclaimer: The following news is paid for and /or published as information only for our readers.Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All Investment involves risk and possible loss of all investment. Disclaimer in full, Investorideas.com Disclosure Please read individual disclosures for featured stocks.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info
June 27, 2013 (Investorideas.com Newswire) SoundView Technology Group: Since initially covering the arrival of cloud-based technology for physical security back in October of 2012 the market in general and Viscount Systems (VSYS) in particular have been developing faster than expected.
Physical security and access control one of the last non-digital, proprietary and very large markets that is now shifting over to software and internet based solutions that leverage smartphones and IP networks. Viscount is the only company that has developed a pure software/internet solution.
Recently they have announced a partnership with Microsoft to be a key component of their Global Security Operations Center . We expect this agreement to be a building block to additional agreements with Microsoft (who with Active Directory already holds the keys to the digital security kingdom.) Viscount is also developing relationships with all the existing large players who are likely to use the Viscount solution for access control as part of their overall proposals.
Near-term business trends have been very positive with a reported pipeline of over $12M (versus their current revenue run rate of $4M/year). The next few quarters will be an important test for the expanded and experienced management team but the momentum and market is clearly on their side.
Viscount also has extensive patent protection (60 filed claims) that will help protect them and make them a more attractive partner to the massive firms serving the industry with old technology (Honeywell, Johnson Controls, ASSA ABLOY) and IT firms like Cisco that have tried to approach the market but whose solutions have been wanting.
Viscount stock has moved up nicely since our initial coverage report but remains well below our near-term expectation of $0.26 and our intrinsic value (IV) estimate of $0.82 for 2014.
Our brief update on current trends is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_June_2013.pdf
The original 20-page overview report is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_Oct_11_2012.pdf
Any questions please contact:
Kris Tuttle
Director of Research
SoundView Technology Group
kris@soundview.co
617-828-6462
More Info:
This news is published on the Investorideas.com Newswire and its syndicated partner network
News now!
Get Free investor news and stock alerts: Sign up here
Disclaimer: The following news is paid for and /or published as information only for our readers.Investorideas.com is a third party publisher of news and research. Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All Investment involves risk and possible loss of all investment. Disclaimer in full, Investorideas.com Disclosure Please read individual disclosures for featured stocks.
BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info
Investorideas.com - Major Beach Soccer, Farpost Soccer Renew Partnership
Investorideas.com - Major Beach Soccer, Farpost Soccer Renew Partnership
Major Beach Soccer, Farpost Soccer Renew Partnership
Farpost remains official goal provider of MBS
TAMPA, Fla. - June 27, 2013 (www.investorideas.com newswire) Major Beach Soccer is proud to announce the renewal of its partnership with Farpost Soccer Company as the official Major Beach Soccer goal supplier through the 2013 season. British Columbia-based Farpost Soccer Company returns for a third season as the official goal supplier of Major Beach Soccer, and also becomes a strategic partner of United Soccer Leagues.
"MBS is extremely lucky to have a partner such as Farpost Soccer Company to help us grow the game of beach soccer in North America ," MBS Founder and Director Peter Mellor said. "Farpost Soccer goals provide our events with goals that are durable, mobile, flexible and easy to set up and take down, which adds tremendous professionalism and efficiency to our operation."
Founded in 1999, Farpost Soccer Company started with the idea of creating a safe, portable goal that would be easy to transport, set up and take down. Today, more than 600 clubs throughout North America utilize Farpost goals for their programs including the Vancouver Whitecaps of Major League Soccer and the Manchester United Soccer Schools.
"We are proud to support Major Beach Soccer and USL," Farpost Soccer Company Owner Michael Cash said. "Being part of this event on an ongoing basis allows us the opportunity to reach new players and fans of the sport while displaying the versatility of our products. It’s all about the love of the game to us."
Major Beach Soccer is in its 23rd year of bringing the top beach soccer tournament action to Florida ’s shores. Registration is open at www.majorbeachsoccer.com for this year’s remaining qualifying tournaments in Clearwater Beach (July 12-14) and Fort Myers Beach (July 27-28).
The third annual MBS National Championship will set the bar even higher in 2013 with the addition of the Coed Over 30 Division to go along with the U14 through U18 boys and girls divisions. The inaugural MBS National Championship in 2011 featured 12 teams, with that number growing to 38 in 2012.
MBS is also supported by Nike, Saint Leo University , the St. Petersburg/Clearwater Sports Commission, Volusia County , the Lee County Sports Authority, Soccer on the Beach, Soccer in the Sand and the Long Island Rough Riders.
Major Beach Soccer
Created by USL Technical Director Peter Mellor, Major Beach Soccer joined USL in 2010. A fixture on Florida beaches for the past 23 years, Major Beach Soccer events feature teams competing five-on-five in 30-minute games with prizes for champions and runners-up in all age groups. Flicks and acrobatic bicycle kicks are the norm in beach soccer, where the fields and goals are small but the action is nonstop.
MBS Public Relations - Jay Preble / Seth Witkowicz / Nicholas Murray - Tampa , FL - 813.963.3909 - Twitter: @MBSsoccer
About Farpost Soccer Company
Farpost Soccer Company started in 1999 as a manufacturer of aluminum, portable, collapsable soccer goals that can be assembled in less than 5 minutes and taken down in under 4 minutes. Professional clubs like the Seattle Sounders FC, Vancouver Whitecaps FC and San Jose Earthquakes use Farpost soccer goals in some of their training programs and over 600 youth soccer clubs in North America use Farpost soccer goals in their smaller-sided games, training and tournaments. The people at Farpost Soccer Goals take pride in delivering a high quality portable soccer goal that is recommended to any coach looking for a reliable, durable, high quality soccer goal that will enhance the training experience for his/her players. www.farpostgoals.com
Contact:
Michael Cash
Farpost Soccer Company
mcash@farpostgoals.com
12740 Trites Road
Richmond, BC V7E 3R8
1-877-241-0121
More Info:
Major Beach Soccer, Farpost Soccer Renew Partnership
Farpost remains official goal provider of MBS
TAMPA, Fla. - June 27, 2013 (www.investorideas.com newswire) Major Beach Soccer is proud to announce the renewal of its partnership with Farpost Soccer Company as the official Major Beach Soccer goal supplier through the 2013 season. British Columbia-based Farpost Soccer Company returns for a third season as the official goal supplier of Major Beach Soccer, and also becomes a strategic partner of United Soccer Leagues.
"MBS is extremely lucky to have a partner such as Farpost Soccer Company to help us grow the game of beach soccer in North America ," MBS Founder and Director Peter Mellor said. "Farpost Soccer goals provide our events with goals that are durable, mobile, flexible and easy to set up and take down, which adds tremendous professionalism and efficiency to our operation."
Founded in 1999, Farpost Soccer Company started with the idea of creating a safe, portable goal that would be easy to transport, set up and take down. Today, more than 600 clubs throughout North America utilize Farpost goals for their programs including the Vancouver Whitecaps of Major League Soccer and the Manchester United Soccer Schools.
"We are proud to support Major Beach Soccer and USL," Farpost Soccer Company Owner Michael Cash said. "Being part of this event on an ongoing basis allows us the opportunity to reach new players and fans of the sport while displaying the versatility of our products. It’s all about the love of the game to us."
Major Beach Soccer is in its 23rd year of bringing the top beach soccer tournament action to Florida ’s shores. Registration is open at www.majorbeachsoccer.com for this year’s remaining qualifying tournaments in Clearwater Beach (July 12-14) and Fort Myers Beach (July 27-28).
The third annual MBS National Championship will set the bar even higher in 2013 with the addition of the Coed Over 30 Division to go along with the U14 through U18 boys and girls divisions. The inaugural MBS National Championship in 2011 featured 12 teams, with that number growing to 38 in 2012.
MBS is also supported by Nike, Saint Leo University , the St. Petersburg/Clearwater Sports Commission, Volusia County , the Lee County Sports Authority, Soccer on the Beach, Soccer in the Sand and the Long Island Rough Riders.
Major Beach Soccer
Created by USL Technical Director Peter Mellor, Major Beach Soccer joined USL in 2010. A fixture on Florida beaches for the past 23 years, Major Beach Soccer events feature teams competing five-on-five in 30-minute games with prizes for champions and runners-up in all age groups. Flicks and acrobatic bicycle kicks are the norm in beach soccer, where the fields and goals are small but the action is nonstop.
MBS Public Relations - Jay Preble / Seth Witkowicz / Nicholas Murray - Tampa , FL - 813.963.3909 - Twitter: @MBSsoccer
About Farpost Soccer Company
Farpost Soccer Company started in 1999 as a manufacturer of aluminum, portable, collapsable soccer goals that can be assembled in less than 5 minutes and taken down in under 4 minutes. Professional clubs like the Seattle Sounders FC, Vancouver Whitecaps FC and San Jose Earthquakes use Farpost soccer goals in some of their training programs and over 600 youth soccer clubs in North America use Farpost soccer goals in their smaller-sided games, training and tournaments. The people at Farpost Soccer Goals take pride in delivering a high quality portable soccer goal that is recommended to any coach looking for a reliable, durable, high quality soccer goal that will enhance the training experience for his/her players. www.farpostgoals.com
Contact:
Michael Cash
Farpost Soccer Company
mcash@farpostgoals.com
12740 Trites Road
Richmond, BC V7E 3R8
1-877-241-0121
More Info:
Investorideas.com - Viscount Systems (VSYS) - Emerging as the "Intel Inside" of Cloud Secure Access
Investorideas.com - Viscount Systems (VSYS) - Emerging as the "Intel Inside" of Cloud Secure Access
June 27, 2013 (Investorideas.com Newswire) SoundView Technology Group: Since initially covering the arrival of cloud-based technology for physical security back in October of 2012 the market in general and Viscount Systems (VSYS) in particular have been developing faster than expected.
Physical security and access control one of the last non-digital, proprietary and very large markets that is now shifting over to software and internet based solutions that leverage smartphones and IP networks. Viscount is the only company that has developed a pure software/internet solution.
Recently they have announced a partnership with Microsoft to be a key component of their Global Security Operations Center . We expect this agreement to be a building block to additional agreements with Microsoft (who with Active Directory already holds the keys to the digital security kingdom.) Viscount is also developing relationships with all the existing large players who are likely to use the Viscount solution for access control as part of their overall proposals.
Near-term business trends have been very positive with a reported pipeline of over $12M (versus their current revenue run rate of $4M/year). The next few quarters will be an important test for the expanded and experienced management team but the momentum and market is clearly on their side.
Viscount also has extensive patent protection (60 filed claims) that will help protect them and make them a more attractive partner to the massive firms serving the industry with old technology (Honeywell, Johnson Controls, ASSA ABLOY) and IT firms like Cisco that have tried to approach the market but whose solutions have been wanting.
Viscount stock has moved up nicely since our initial coverage report but remains well below our near-term expectation of $0.26 and our intrinsic value (IV) estimate of $0.82 for 2014.
Our brief update on current trends is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_June_2013.pdf
The original 20-page overview report is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_Oct_11_2012.pdf
Any questions please contact:
Kris Tuttle
Director of Research
SoundView Technology Group
kris@soundview.co
617-828-6462
June 27, 2013 (Investorideas.com Newswire) SoundView Technology Group: Since initially covering the arrival of cloud-based technology for physical security back in October of 2012 the market in general and Viscount Systems (VSYS) in particular have been developing faster than expected.
Physical security and access control one of the last non-digital, proprietary and very large markets that is now shifting over to software and internet based solutions that leverage smartphones and IP networks. Viscount is the only company that has developed a pure software/internet solution.
Recently they have announced a partnership with Microsoft to be a key component of their Global Security Operations Center . We expect this agreement to be a building block to additional agreements with Microsoft (who with Active Directory already holds the keys to the digital security kingdom.) Viscount is also developing relationships with all the existing large players who are likely to use the Viscount solution for access control as part of their overall proposals.
Near-term business trends have been very positive with a reported pipeline of over $12M (versus their current revenue run rate of $4M/year). The next few quarters will be an important test for the expanded and experienced management team but the momentum and market is clearly on their side.
Viscount also has extensive patent protection (60 filed claims) that will help protect them and make them a more attractive partner to the massive firms serving the industry with old technology (Honeywell, Johnson Controls, ASSA ABLOY) and IT firms like Cisco that have tried to approach the market but whose solutions have been wanting.
Viscount stock has moved up nicely since our initial coverage report but remains well below our near-term expectation of $0.26 and our intrinsic value (IV) estimate of $0.82 for 2014.
Our brief update on current trends is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_June_2013.pdf
The original 20-page overview report is available here: http://s3.amazonaws.com/ Published_Research/ Viscount_VSYS_Report_Oct_11_2012.pdf
Any questions please contact:
Kris Tuttle
Director of Research
SoundView Technology Group
kris@soundview.co
617-828-6462
Investorideas.com - New Development for Treatment and Testing of Hepatitis C virus (HCV)
Investorideas.com - New Development for Treatment and Testing of Hepatitis C virus (HCV)
Aethlon Medical (OTCQB: AEMD) Reports FDA approval of IDE to Treat Hepatitis C (HCV) Patients
Abbott Laboratories (NYSE: ABT) Announces First U.S. Food and Drug Administration (FDA)approved hepatitis C genotyping test is now available in the U.S.
U.S. Preventive Services Task Force Issues Final Recommendation Statement on Screening for Hepatitis C Virus Infection in Adults
Point Roberts WA, New York, NY –June 27, 2013 – (www.investorideas.com newswire). Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, discusses recent news and developments for the treatment and testing of Hepatitis C virus (HCV) . Aethlon Medical, Inc. (OTCQB: AEMD) reported FDA approval of an Investigational Device Exemption (IDE) to treat Hepatitis C (HCV) patients and Abbott Laboratories (NYSE: ABT) announced the first U.S. FDA approved hepatitis C genotyping test is now available in the U.S. to help physicians improve patient care.
According to the CDC, about 3 million adults in the US are infected with the hepatitis C virus, most are baby boomers. Hepatitis C is a serious virus infection that over time can cause liver damage and even liver cancer. Early treatment can prevent this damage. Too many people with hepatitis C do not know they are infected, so they don't get the medical care they need. Once infected with the hepatitis C virus, nearly 8 in 10 people remain infected for life.
Earlier this week the U.S. Preventive Services Task Force made headlines as it made statements recommending screening for hepatitis C virus (HCV) infection in persons at high risk for infection. The USPSTF also recommended offering one-time screening for HCV infection to adults born between 1945 and 1965.
“Millions of people in the United States are infected with hepatitis C, and many are unaware of their condition, in large part because they may not have any symptoms,” says Task Force member Kirsten Bibbins-Domingo, Ph.D., M.D. “Hepatitis C infection is a leading cause of liver damage, liver cancer, and liver transplants in the United States. Screening for hepatitis C can help people who are infected live longer, healthier lives.”
Aethlon Medical, Inc. (OTCQB: AEMD), reported this week that the FDA has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
Last week Abbott (NYSE: ABT) reported it has introduced the first FDA-approved hepatitis C virus (HCV) genotyping test for patients in the United States. Abbott's fully automated RealTime HCV Genotype II test determines the specific type or strain (referred to as the genotype) of the HCV virus present in the blood of an HCV-infected individual. Genotyping the HCV virus provides physicians with important information they can use to create a personalized, targeted diagnosis and treatment path to improve clinical outcomes.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About Abbott
Abbott Laboratories (NYSE: ABT)
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000.
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source – www.Investorideas.com
Aethlon Medical (OTCQB: AEMD) Reports FDA approval of IDE to Treat Hepatitis C (HCV) Patients
Abbott Laboratories (NYSE: ABT) Announces First U.S. Food and Drug Administration (FDA)approved hepatitis C genotyping test is now available in the U.S.
U.S. Preventive Services Task Force Issues Final Recommendation Statement on Screening for Hepatitis C Virus Infection in Adults
Point Roberts WA, New York, NY –June 27, 2013 – (www.investorideas.com newswire). Investorideas.com, an investor research portal specializing in investing ideas in leading sectors including biotech and medical technology stocks, discusses recent news and developments for the treatment and testing of Hepatitis C virus (HCV) . Aethlon Medical, Inc. (OTCQB: AEMD) reported FDA approval of an Investigational Device Exemption (IDE) to treat Hepatitis C (HCV) patients and Abbott Laboratories (NYSE: ABT) announced the first U.S. FDA approved hepatitis C genotyping test is now available in the U.S. to help physicians improve patient care.
According to the CDC, about 3 million adults in the US are infected with the hepatitis C virus, most are baby boomers. Hepatitis C is a serious virus infection that over time can cause liver damage and even liver cancer. Early treatment can prevent this damage. Too many people with hepatitis C do not know they are infected, so they don't get the medical care they need. Once infected with the hepatitis C virus, nearly 8 in 10 people remain infected for life.
Earlier this week the U.S. Preventive Services Task Force made headlines as it made statements recommending screening for hepatitis C virus (HCV) infection in persons at high risk for infection. The USPSTF also recommended offering one-time screening for HCV infection to adults born between 1945 and 1965.
“Millions of people in the United States are infected with hepatitis C, and many are unaware of their condition, in large part because they may not have any symptoms,” says Task Force member Kirsten Bibbins-Domingo, Ph.D., M.D. “Hepatitis C infection is a leading cause of liver damage, liver cancer, and liver transplants in the United States. Screening for hepatitis C can help people who are infected live longer, healthier lives.”
Aethlon Medical, Inc. (OTCQB: AEMD), reported this week that the FDA has approved an Investigational Device Exemption (IDE) that allows the Company to initiate human feasibility studies of the Aethlon Hemopurifier® in the United States. The Hemopurifier® is a first-in-class medical device that targets the rapid elimination of life-threatening infectious disease and cancer glycopathogens from circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety of Hemopurifier therapy. Successful completion of the feasibility study will set the stage for Aethlon to conduct pivotal studies required for market clearance to treat HCV and potentially other disease conditions.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
Last week Abbott (NYSE: ABT) reported it has introduced the first FDA-approved hepatitis C virus (HCV) genotyping test for patients in the United States. Abbott's fully automated RealTime HCV Genotype II test determines the specific type or strain (referred to as the genotype) of the HCV virus present in the blood of an HCV-infected individual. Genotyping the HCV virus provides physicians with important information they can use to create a personalized, targeted diagnosis and treatment path to improve clinical outcomes.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to address infectious disease and cancer, and a medical device being developed under a 5-year contract with DARPA to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About Abbott
Abbott Laboratories (NYSE: ABT)
Abbott is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 70,000.
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013 http://www.investorideas.com/About/Disclaimer.asp BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
800-665-0411 - or 212-822-8842Source – www.Investorideas.com
Investorideas.com Newswire - Obama's Climate Change Policy and the Global Race for Renewable Energy
Investorideas.com Newswire - Obama's Climate Change Policy and the Global Race for Renewable Energy
Clean Energy Stocks Blog for Green Investors: part of the Investorideas.com cleantech investor stock research content. Research Renewable Energy and water stocks as an Investor Ideas member and gain access to global green stock directories- get login access to all 4 cleantech stock directories including water stocks and renewable energy stocks : http://www.investorideas.com/membership/.Disclaimer: this is not a solicitation to buy or sell stocks, or an endorsement for any company.
Clean Energy Stocks Blog for Green Investors: part of the Investorideas.com cleantech investor stock research content. Research Renewable Energy and water stocks as an Investor Ideas member and gain access to global green stock directories- get login access to all 4 cleantech stock directories including water stocks and renewable energy stocks : http://www.investorideas.com/membership/.Disclaimer: this is not a solicitation to buy or sell stocks, or an endorsement for any company.
Tuesday, June 25, 2013
Trading Alert: Aethlon Medical, Inc. (OTCQB: AEMD) Spikes on FDA News
Point Roberts WA, New York, NY - June 25, 2013 (Investorideas.com newswire) - Investorideas.com, an investor
research portal specializing in investing ideas in leading sectors
including biotech and medical technology stocks, issues a trading alert
for Aethlon Medical, Inc. (OTCQB: AEMD), trading at $0.1199 0.0189 or 18.71% as of 11:00AM EDT on over 796,000 shares following FDA news.
The company reported today that the United States Food and Drug
Administration (FDA) has approved an Investigational Device Exemption
(IDE) that allows the Company to initiate human feasibility studies of
the Aethlon Hemopurifier® in the United States. The Hemopurifier ® is a
first-in-class medical device that targets the rapid elimination of
life-threatening infectious disease and cancer glycopathogens from
circulation.
Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of the feasibility study
will set the stage for Aethlon to conduct pivotal studies required for
market clearance to treat HCV and potentially other disease conditions.
About Aethlon Medical (OTCQB: AEMD)
Aethlon Medical creates innovative
medical devices that address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions. Our Aethlon ADAPT™
System is a revenue-stage technology platform that provides the basis
for a new class of devices the rapid, yet selective removal of disease
promoting particles from the entire circulatory system. At present, The
Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to
address infectious disease and cancer, and a medical device being
developed under a 5-year contract with DARPA to reduce the incidence of
sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy, beverage stocks and more.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: Investorideas has been compensated by AEMD for
news distribution and content publishing: three thousand per month
effective June 2013 http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar
800-665-0411 or 212-822-8842
Source www.Investorideas.com
research portal specializing in investing ideas in leading sectors
including biotech and medical technology stocks, issues a trading alert
for Aethlon Medical, Inc. (OTCQB: AEMD), trading at $0.1199 0.0189 or 18.71% as of 11:00AM EDT on over 796,000 shares following FDA news.Under the feasibility study protocol, Aethlon will enroll ten end stage renal disease (ESRD) patients who are infected with the Hepatitis C virus (HCV) to demonstrate the safety
of Hemopurifier therapy. Successful completion of the feasibility study
will set the stage for Aethlon to conduct pivotal studies required for
market clearance to treat HCV and potentially other disease conditions.
About Aethlon Medical (OTCQB: AEMD) Aethlon Medical creates innovative
medical devices that address unmet medical needs in cancer, infectious
disease, and other life-threatening conditions. Our Aethlon ADAPT™
System is a revenue-stage technology platform that provides the basis
for a new class of devices the rapid, yet selective removal of disease
promoting particles from the entire circulatory system. At present, The
Aethlon ADAPT product pipeline includes the Aethlon Hemopurifier to
address infectious disease and cancer, and a medical device being
developed under a 5-year contract with DARPA to reduce the incidence of
sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.About InvestorIdeas.com: Big Ideas for global investors
InvestorIdeas.com is a leader in investor stock research by sector, featuring stock news, commentary and trading alerts in leading sectors including biotech, tech, mining, energy, water, renewable energy
, beverage stocks and more.Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Follow Investorideas.com News on Linkedin.com/today at http://www.linkedin.com/today/investorideas.com
Sign up for free stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech and medical technology stocks:
http://www.investorideas.com/membership/
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: Investorideas has been compensated by AEMD for
news distribution and content publishing: three thousand per month
effective June 2013 http://www.investorideas.com/About/Disclaimer.asp
BC Residents and Investor Disclaimer : Effective September 15 2008 -
all BC investors should review all OTC and Pink sheet listed companies
for adherence in new disclosure filings and filing appropriate documents
with Sedar800-665-0411 or 212-822-8842
Source www.Investorideas.com
Medical Technology Stock Breaking News: Aethlon Medical (OTCQB: AEMD) Reports FDA Approval of IDE to Treat Hepatitis C (HCV) Patients
SAN DIEGO - June 25, 2013 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCQB: AEMD),
announced today that the United States Food and Drug Administration
(FDA) has approved an Investigational Device Exemption (IDE) that allows
the Company to initiate human feasibility studies of the Aethlon
Hemopurifier® in the United States. The Hemopurifier® is a
first-in-class medical device that targets the rapid elimination of
life-threatening infectious disease and cancer glycopathogens from
circulation.
Under the feasibility study protocol, Aethlon will enroll ten end
stage renal disease (ESRD) patients who are infected with the Hepatitis C
virus (HCV) to demonstrate the safety of Hemopurifier therapy .
Successful completion of the feasibility study will set the stage for
Aethlon to conduct pivotal studies required for market clearance to
treat HCV and potentially other disease conditions.
"Obtaining FDA's permission to initiate human studies has been our most important objective for several years," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "I salute the perseverance of our dedicated Aethlon team, their families, and loyal shareholders whose support allowed us to endure the challenges of navigating through FDA. We plan to reward your faith with clinical execution and progression toward a marketable therapy in the United States."
Specific to the treatment of HCV, the Hemopurifier is uniquely positioned as an adjuvant to be incorporated with either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens without adding drug toxicity. In addition to augmenting the early viral kinetic response to SOC, the Hemopurifier is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes resistance to drug regimens. Additionally, the Hemopurifier addresses the large population of HCV-infected ESRD patients for which SOC and emerging all-antiviral strategies may be contraindicated or not yet cleared. According to the World Health Organization (WHO), HCV is a blood-borne pathogen that affects upwards of 170 million persons, or 2-3% of the world's population. It is a leading cause of cirrhosis and liver transplantation.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
In studies previously conducted in India, Hemopurifier therapy was demonstrated to be well tolerated in treatment naïve HIV and HCV-infected ESRD patients when included during normally scheduled four-hour dialysis sessions. In these studies, average per treatment viral load reductions were observed to exceed 50% in both disease conditions. In follow-on studies of non-ESRD individuals infected with HCV, a three-treatment protocol of Hemopurifier therapy in combination with interferon-based standard of care (SOC) resulted in undetectable HCV in as little as seven days in hardest to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six-hour treatment.
"Aethlon Medical has been laying the groundwork necessary to implement the now approved clinical trial protocol for several years" said Rod Kenley, Aethlon's President. "We are finally able to move forward with our contract research and clinical partners in finalizing all of the activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done, today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization."
The feasibility study protocol was originally designed as a human safety challenge and model for addressing drug and vaccine resistant bioterror and emerging pandemic threats such as the Middle East Respiratory Syndrome (MERS) now spreading overseas. In vitro studies conducted by leading government and non-government researchers have demonstrated that the Hemopurifier is able to capture a broad-spectrum of some of world's deadliest viral pathogens. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), H1N1 swine flu virus, the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV) and Vaccinia and Monkeypox (MPV), which serve as models for human smallpox infection. Human efficacy studies are not permissible against high-threat bioterror and pandemic threats.
The Hemopurifier is also being tested for its ability to capture glycopathogen targets that initiate or enhance the progression of sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA). Sepsis is a life-threatening illness triggered by an overwhelming infection of the bloodstream. Globally, there are 18 million cases of diagnosed sepsis per year and the incidence is rising at 8 to 10% annually.
In cancer, the Hemopurifier has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier is positioned as an adjunct to improve established cancer treatment regimens. In vitro studies to date have also documented that the Hemopurifier captures exosomes underlying lymphoma, melanoma, ovarian, and breast cancer.
In design, the Aethlon Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of advanced plasma membrane technology. The design allows for extracorporeal therapeutic delivery to occur on standard CRRT and dialysis instruments already located in hospitals and clinics worldwide. The mechanism of the Hemopurifier to rapidly eliminate a broad-spectrum disease targets is based on GNA's ability to selectively bind unique high mannose signatures that are abundant on the surface of cancer-secreted exosomes and glycoproteins that reside on the outer membrane of infectious viral pathogens.
The Company will continue to update shareholders, constituents and potential study participants as feasibility study milestones are achieved, including naming a principal investigator, initiation of patient enrollment and the beginning of treatments with the Aethlon Hemopurifier.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
"Obtaining FDA's permission to initiate human studies has been our most important objective for several years," stated Jim Joyce, Chairman and CEO of Aethlon Medical. "I salute the perseverance of our dedicated Aethlon team, their families, and loyal shareholders whose support allowed us to endure the challenges of navigating through FDA. We plan to reward your faith with clinical execution and progression toward a marketable therapy in the United States."
Specific to the treatment of HCV, the Hemopurifier is uniquely positioned as an adjuvant to be incorporated with either interferon-based standard of care (SOC) or emerging all-antiviral drug regimens without adding drug toxicity. In addition to augmenting the early viral kinetic response to SOC, the Hemopurifier is a candidate solution for viral rebound patients who traditionally are forced to discontinue therapy at the point HCV establishes resistance to drug regimens. Additionally, the Hemopurifier addresses the large population of HCV-infected ESRD patients for which SOC and emerging all-antiviral strategies may be contraindicated or not yet cleared. According to the World Health Organization (WHO), HCV is a blood-borne pathogen that affects upwards of 170 million persons, or 2-3% of the world's population. It is a leading cause of cirrhosis and liver transplantation.
The FDA approved Hemopurifier therapy feasibility study calls for a single-site enrollment of ten HCV-infected end-stage renal disease (ESRD) patients who have not received any pharmaceutical therapy for their HCV infection for at least 30 days. The protocol consists of a control phase which consists of three consecutive standard dialysis treatments during week one followed by the inclusion of the Hemopurifier during a total of six dialysis sessions conducted during weeks two and three. The rate of adverse events observed during the Hemopurifier therapy phase will be compared to the rate experienced during the control phase. Per-treatment changes of viral load will be observed through quantitative PCR analysis. Additionally, Aethlon may also choose to quantitate HCV viral copies captured within the Hemopurifier during each treatment session.
In studies previously conducted in India, Hemopurifier therapy was demonstrated to be well tolerated in treatment naïve HIV and HCV-infected ESRD patients when included during normally scheduled four-hour dialysis sessions. In these studies, average per treatment viral load reductions were observed to exceed 50% in both disease conditions. In follow-on studies of non-ESRD individuals infected with HCV, a three-treatment protocol of Hemopurifier therapy in combination with interferon-based standard of care (SOC) resulted in undetectable HCV in as little as seven days in hardest to treat genotype-1 patients. The studies also documented the ability of the Hemopurifier to capture as many as 300 billion HCV copies during a single six-hour treatment.
"Aethlon Medical has been laying the groundwork necessary to implement the now approved clinical trial protocol for several years" said Rod Kenley, Aethlon's President. "We are finally able to move forward with our contract research and clinical partners in finalizing all of the activities that can now take place prior to initiating treatment of the first patient. While there is still some work to be done, today the biggest hurdle has been cleared and we are anxious to make rapid progress towards commercialization."
The feasibility study protocol was originally designed as a human safety challenge and model for addressing drug and vaccine resistant bioterror and emerging pandemic threats such as the Middle East Respiratory Syndrome (MERS) now spreading overseas. In vitro studies conducted by leading government and non-government researchers have demonstrated that the Hemopurifier is able to capture a broad-spectrum of some of world's deadliest viral pathogens. These include: Dengue hemorrhagic fever (DHF), Ebola hemorrhagic fever (EHF), Lassa hemorrhagic fever (LHF), H5N1 avian influenza (Bird Flu), H1N1 swine flu virus, the reconstructed 1918 influenza virus (r1918), West Nile virus (WNV) and Vaccinia and Monkeypox (MPV), which serve as models for human smallpox infection. Human efficacy studies are not permissible against high-threat bioterror and pandemic threats.
The Hemopurifier is also being tested for its ability to capture glycopathogen targets that initiate or enhance the progression of sepsis through a contract with the Defense Advanced Research Projects Agency (DARPA). Sepsis is a life-threatening illness triggered by an overwhelming infection of the bloodstream. Globally, there are 18 million cases of diagnosed sepsis per year and the incidence is rising at 8 to 10% annually.
In cancer, the Hemopurifier has been discovered to capture tumor-derived exosomes underlying several forms of cancer. Tumor-derived exosomes have recently emerged to be a vital therapeutic target in cancer care. These microvesicular particles suppress the immune response in cancer patients through apoptosis of immune cells and their quantity in circulation correlates directly with disease progression. Beyond possessing immunosuppressive properties, tumor-derived exosomes facilitate tumor growth, metastasis, and the development of drug resistance. By addressing this unmet medical need, the Hemopurifier is positioned as an adjunct to improve established cancer treatment regimens. In vitro studies to date have also documented that the Hemopurifier captures exosomes underlying lymphoma, melanoma, ovarian, and breast cancer.
In design, the Aethlon Hemopurifier consists of the affinity lectin Galanthus nivalis agglutinin (GNA) immobilized in the outer-capillary space of advanced plasma membrane technology. The design allows for extracorporeal therapeutic delivery to occur on standard CRRT and dialysis instruments already located in hospitals and clinics worldwide. The mechanism of the Hemopurifier to rapidly eliminate a broad-spectrum disease targets is based on GNA's ability to selectively bind unique high mannose signatures that are abundant on the surface of cancer-secreted exosomes and glycoproteins that reside on the outer membrane of infectious viral pathogens.
The Company will continue to update shareholders, constituents and potential study participants as feasibility study milestones are achieved, including naming a principal investigator, initiation of patient enrollment and the beginning of treatments with the Aethlon Hemopurifier.
About Aethlon Medical
Aethlon Medical creates innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of devices the rapid, yet selective removal of disease promoting particles from the entire circulatory system. At present, The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer, and a medical device being developed under a 5-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers. For more information, please visit www.aethlonmedical.com.
Certain statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the company can successfully protect its intellectual property, that removal of exosomes from the human body will impact or lead to successful treatment of cancer, or that exosomes are the cause of tumor growth and progression, that the FDA will not approve the initiation of the Company's clinical programs or provide market clearance of the company's products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy, the Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Published at Investorideas.com newswire
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer / Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by AEMD for news distribution and content publishing: three thousand per month effective June 2013
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar
China Social Media Stock Alert: UMeWorld's (OTCQB:UMEWF) Video Platform Reaches 2.7 Million Unique Visitors
HONG KONG - June 25, 2013 (Investorideas.com newswire) Chinese Internet Stock Alert : MeWorld Limited (OTCQB: UMEWF)
is pleased to announce that UMeLook.com, an online video platform
focused on bringing foreign video content to China, has reached 2.7
million unique visitors since launching the newly redesigned site on May
24, 2013. UMeLook.com also enjoyed over 9.4 million page views in the
same period. The page views have been steadily increasing to over
500,000 a day.
"I'm enormously pleased that UMeLook.com has reached this
impressive milestone," said Michael Lee, President & CEO of
UMeWorld. "This traffic number is all the more impressive given that it
has been achieved in just over one month. However, this is just a
sign-post on the way to UMeLook.com becoming a global e-commerce
platform assisting small and medium brands worldwide to expand into the
Chinese market."
About UMeWorld
UMeWorld's mission is to facilitate the interaction between people -- "You" and "Me," through its digital platform. Currently, UMeWorld operates UMeLook (www.umelook.com), an online
video platform focused on bringing foreign video content to China.
UMeLook is deployed through a sophisticated CDN (Content Delivery
Network) with broad coverage throughout mainland China, Hong Kong &
Taiwan. UMeLook plans to be a source of foreign video content for the
Chinese viewer across any Internet-enabled device in China. UMeWorld
intends to focus its future operations on digital media and the digital
education market.
Forward Looking Statement
Statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance
or achievements. We assume no obligation to publicly update or revise
any forward-looking statements in order to reflect any event or
circumstance that may arise after the date of this release, even if new
information becomes available in the future. For a more detailed
description of the risk and uncertainties affecting the Company,
reference is made to the Company's reports filed from time to time with
the Securities and Exchange Commission.
For more information, please contact:
UMeWorld Limited
E-mail: info@UMeWorld.com
Published at Investorideas.com – Big Ideas for Global Investors
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: UMEWF compensates Investorideas.com for news publication and syndication : two thousand per month
BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Stock Alert : MeWorld Limited (OTCQB: UMEWF)
is pleased to announce that UMeLook.com, an online video platform
focused on bringing foreign video content to China, has reached 2.7
million unique visitors since launching the newly redesigned site on May
24, 2013. UMeLook.com also enjoyed over 9.4 million page views in the
same period. The page views have been steadily increasing to over
500,000 a day.About UMeWorld
UMeWorld's mission is to facilitate the interaction between people -- "You" and "Me," through its digital platform. Currently, UMeWorld operates UMeLook (www.umelook.com), an online
video platform focused on bringing foreign video content to China.
UMeLook is deployed through a sophisticated CDN (Content Delivery
Network) with broad coverage throughout mainland China, Hong Kong &
Taiwan. UMeLook plans to be a source of foreign video content for the
Chinese viewer across any Internet-enabled device in China. UMeWorld
intends to focus its future operations on digital media and the digital
education market.Forward Looking Statement
Statements in this press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance
or achievements. We assume no obligation to publicly update or revise
any forward-looking statements in order to reflect any event or
circumstance that may arise after the date of this release, even if new
information becomes available in the future. For a more detailed
description of the risk and uncertainties affecting the Company,
reference is made to the Company's reports filed from time to time with
the Securities and Exchange Commission.For more information, please contact:
UMeWorld Limited
E-mail: info@UMeWorld.com
Published at Investorideas.com – Big Ideas for Global Investors
Sign up for the free investor news and stock alerts at Investorideas.com
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: UMEWF compensates Investorideas.com for news publication and syndication : two thousand per month
BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894Monday, June 24, 2013
Solar Stock Alert: XsunX (OTCQB: XSNX) Reports CIGSolar® Producing Near Identical CIGS Films to 16.4% NREL Samples
June 24, 2013 (Investorideas.com renewable energy newswire) XsunX, Inc. (OTCQB: XSNX)
issues the following update from Tom Djokovich, CEO: Lately our updates
have centered on our developing business opportunities, key markets,
and the stabilizing solar market. In the background, we have been
working full time with the CIGSolar® evaporator and we are excited to
let you know that we are seeing some outstanding results.
Since the completion of the CIGSolar® evaporator assembly, we have
carried out literally hundreds of incremental steps aimed toward
establishing benchmarks, calibrating performance, and identifying or
implementing potential improvements across our entire suite of system capabilities from material transport to CIGS deposition.
Our objective was to get the tool assembled, working, and producing results on par with the results we achieved during the initial technology development phase. The good news is that the tedious process of what seemed like endless incremental and iterative steps is now producing those types of results. Our internal testing of films is showing near identical film composition results to those recorded in a sample we provided to the National Renewable Energy Laboratory (NREL) during our development phase, which averaged 16.4% efficiency.
Not surprisingly, and we have mentioned this before a few times, our proprietary thermal co-evaporation heating, insulation, and nozzle technology have performed remarkably well and we are excited about our thin film processing results and commercial prospects of our multi-source design.
This progress also shows that we are on the right track and helps to strengthen our marketing capabilities as well as emphasizes our commitment to continued process and system improvements for the benefit our customers.
As always, we are working hard to capitalize the full potential of CIGSolar® for our shareholders and look forward to sharing more progress and news with you in the near future.
Tom Djokovich, CEO
About XsunX (OTCQB: XSNX)
XsunX, Inc. is working to commercialize a new manufacturing process to produce low cost,
high efficiency thin-film Copper Indium Gallium (di) Selenide (CIGS)
thin film solar cells. Our patent-pending processing technology, which
we call CIGSolar®, focuses on the mass production of thin-film CIGS
solar cells utilizing a proprietary multi-area thermal deposition
process to minimize processing defects to create highly uniform CIGS
films. These cells match silicon solar cell dimensions and can be
offered as a non-toxic, high-efficiency and lowest-cost alternative to
the use of silicon solar cells. The company is offering licenses for the
use of the CIGSolar® process technology, and plans to generate revenue
through licensing fees and manufacturing royalties for the use of the
CIGSolar® technology.
To learn more about XsunX's' breakthrough technology please visit http://www.xsunx.com.
Safe Harbor Statement: Matters discussed in this shareholder newsletter contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this shareholder newsletter, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
Published at www.Investorideas.com � Big Ideas for Global Investors
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor
stock research by sector, featuring stock news, commentary and trading
alerts in leading sectors including biotech, tech, mining, energy,
water, renewable energy, beverage stocks and more.
Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by XSNX for news distribution for one month: two thousand dollars
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in
new disclosure filings and filing appropriate documents with Sedar
newswire) XsunX, Inc. (OTCQB: XSNX)
issues the following update from Tom Djokovich, CEO: Lately our updates
have centered on our developing business opportunities, key markets,
and the stabilizing solar market. In the background, we have been
working full time with the CIGSolar® evaporator and we are excited to
let you know that we are seeing some outstanding results. from material transport to CIGS deposition.Our objective was to get the tool assembled, working, and producing results on par with the results we achieved during the initial technology development phase. The good news is that the tedious process of what seemed like endless incremental and iterative steps is now producing those types of results. Our internal testing of films is showing near identical film composition results to those recorded in a sample we provided to the National Renewable Energy Laboratory (NREL) during our development phase, which averaged 16.4% efficiency
.Not surprisingly, and we have mentioned this before a few times, our proprietary thermal co-evaporation heating, insulation, and nozzle technology have performed remarkably well and we are excited about our thin film processing results and commercial prospects of our multi-source design.
This progress also shows that we are on the right track and helps to strengthen our marketing capabilities as well as emphasizes our commitment to continued process and system improvements for the benefit our customers.
As always, we are working hard to capitalize the full potential of CIGSolar® for our shareholders and look forward to sharing more progress and news with you in the near future.
Tom Djokovich, CEO
About XsunX (OTCQB: XSNX)
XsunX, Inc. is working to commercialize a new manufacturing process to produce low cost
,
high efficiency thin-film Copper Indium Gallium (di) Selenide (CIGS)
thin film solar cells. Our patent-pending processing technology, which
we call CIGSolar®, focuses on the mass production of thin-film CIGS
solar cells utilizing a proprietary multi-area thermal deposition
process to minimize processing defects to create highly uniform CIGS
films. These cells match silicon solar cell dimensions and can be
offered as a non-toxic, high-efficiency and lowest-cost alternative to
the use of silicon solar cells. The company is offering licenses for the
use of the CIGSolar® process technology, and plans to generate revenue
through licensing fees and manufacturing royalties for the use of the
CIGSolar® technology.To learn more about XsunX's' breakthrough technology please visit http://www.xsunx.com.
Safe Harbor Statement: Matters discussed in this shareholder newsletter contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this shareholder newsletter, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.
Published at www.Investorideas.com � Big Ideas for Global Investors
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor
stock research by sector, featuring stock news, commentary and trading
alerts in leading sectors including biotech, tech, mining, energy,
water, renewable energy, beverage stocks and more. Sign up for the free investor news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. Disclosure: Investorideas has been compensated by XSNX for news distribution for one month: two thousand dollars
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in
new disclosure filings and filing appropriate documents with Sedar
Stem Cell Stock Alert: BioRestorative Therapies (OTCBB: BRTX) Expands its ThermoStem® Program to 150 Stem Cell Lines
JUPITER, Fla. - June 24, 2013 (Investorideas.com Newswire) BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX),
a life sciences company focused on stem cell-based therapeutics,
announced that it has expanded its ThermoStem® Program by collecting 150
samples of human brown adipose tissue (BAT). For the past year, through
strategic collaboration
and internal BRT efforts, the Company has grown a large library of
human brown fat stem cells. The ThermoStem® Program, which is in the
pre-clinical stage, focuses on the development of therapies using adult
derived stem cells from brown adipose tissue to treat metabolic and
obesity related disorders (particularly focusing on Type 2 Diabetes).
The compilation of a large number and variety of brown fat derived stem
cells allows BRT to study and identify potential cell lines to be used
in developing therapies.
Pre-clinical models indicate that increased amounts of brown fat in
the body may be responsible for additional caloric burning as well as
reduced glucose and lipid levels in the body. Many groups are using BAT
as a tool to further understand the browning effect, wherein a small
molecule or pharmaceutical potentially could be developed to treat
obesity and its associated metabolic disorders. However, BioRestorative
Therapies' novel cellular approach focuses on what appears to be BAT's
innate ability to regulate metabolic homeostasis by using stem cells
isolated from BAT.
Recent published reports have demonstrated that BAT is found in adults and can be routinely isolated. In addition to providing material needed to further advance BRTs pre-clinical models, BioRestorative Therapies' library of stem cells can also provide a valuable and unique resource
in seeking to develop small molecules that activate brown fat and
increase energy expenditure, a strategy for addressing both obesity and
diabetes. The Company's ongoing cell characterizations, collected data,
and stem cells represent a potential supply of necessary controls and
variety of cells for pharmaceutical and other companies embarking on the
small molecule drug development pathway.
Mark Weinreb, Chairman and CEO of BioRestorative Therapies, said, "To our knowledge, we have the largest library of human brown fat stem cell lines known, which represents an enormous research asset in working towards a therapy for metabolic disorders and obesity. Having a large collection of brown fat stem cell lines will be important to accelerate the development of our ThermoStem® Program. Such access also provides opportunities for collaboration and strategic partnerships, because this volume and variety of collections is complementary to large pharmaceutical companies working on small molecule-based programs seeking to treat these disorders."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
under the Stem Pearls® brand at www.stempearls.com.
This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk.
http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online advertising. Disclosure: BioRestorative
has compensated Investoridea for a six month news program ( five
thousand ) to be published on Investorideas.com newswire and syndication
and social media partners.
BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
and internal BRT efforts, the Company has grown a large library of
human brown fat stem cells. The ThermoStem® Program, which is in the
pre-clinical stage, focuses on the development of therapies using adult
derived stem cells from brown adipose tissue to treat metabolic and
obesity related disorders (particularly focusing on Type 2 Diabetes).
The compilation of a large number and variety of brown fat derived stem
cells allows BRT to study and identify potential cell lines to be used
in developing therapies.Recent published reports have demonstrated that BAT is found in adults and can be routinely isolated. In addition to providing material needed to further advance BRTs pre-clinical models, BioRestorative Therapies' library of stem cells can also provide a valuable and unique resource
in seeking to develop small molecules that activate brown fat and
increase energy expenditure, a strategy for addressing both obesity and
diabetes. The Company's ongoing cell characterizations, collected data,
and stem cells represent a potential supply of necessary controls and
variety of cells for pharmaceutical and other companies embarking on the
small molecule drug development pathway.Mark Weinreb, Chairman and CEO of BioRestorative Therapies, said, "To our knowledge, we have the largest library of human brown fat stem cell lines known, which represents an enormous research asset in working towards a therapy for metabolic disorders and obesity. Having a large collection of brown fat stem cell lines will be important to accelerate the development of our ThermoStem® Program. Such access also provides opportunities for collaboration and strategic partnerships, because this volume and variety of collections is complementary to large pharmaceutical companies working on small molecule-based programs seeking to treat these disorders."
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT"), www.biorestorative.com, develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, designed for patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives:
- brtxDISC™ Program (Disc Implanted Stem Cells), a non-surgical treatment for bulging and herniated discs that addresses the gap between non-invasive and invasive back procedures. This research is still in the non-clinical, investigational stage.
- ThermoStem® Program, a treatment for metabolic disorders (diabetes, heart disease, etc.) and obesity using brown fat stem cells. Initial non-clinical research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body.
- brtx-C Cosmetic Program, based on the development of a human cellular extract that, per initial in vitro studies, when applied to human skin cells, appears to cause an increase in the production of collagen and fibronectin, which are proteins that are essential to combating the aging of skin. Potential cosmetic uses are being explored with third parties.
under the Stem Pearls® brand at www.stempearls.com.This press release and the interview contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
Investor Contact:
Adam Holdsworth
ProActive Capital
646.862.4607
adamh@proactivecapital.com
Media Contact:
Sandra Lee
ProActive Capital
646.862.4608
slee@proactivecapital.com
Disclaimer /Disclosure: The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment
involves risk.http://www.investorideas.com/About/Disclaimer.asp
This site is currently compensated by featured companies, news submissions and online
advertising. Disclosure: BioRestorative
has compensated Investoridea for a six month news program ( five
thousand ) to be published on Investorideas.com newswire and syndication
and social media partners.BC Residents and Investor
Disclaimer: Effective September 15 2008 - all BC investors should
review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for
more info: http://www.bcsc.bc.ca/release.aspx?id=6894
Subscribe to:
Posts (Atom)